Clinical trial · Observational
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging
Medical and Economical Impact of Predicting the Response to Anti-angiogenic Treatment in Metastatic Renal Cell Carcinoma Using Functional CT and MRI
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal is to study the impact of functional MRI and CT evaluation of changes in tumor vessels induced by anti-angiogenic treatment in patients with metastatic RCC. The hypothesis is that good responders and poor responders will have different responses induced by anti-angiogenic treatment, and that the detection of theses changes by functional imaging can improve the therapeutic management. Functional CT and MRI will be performed in 200 patients before the beginning of antiangiogenic treatment, 7 days after and every 6 week until tumor progression (as defined by the RECIST criteria). Perfusion and diffusion parameters will be measured using a dedicated software.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- RECIST criteria evolution
- timeFrame
- at day 7 and after every 6 at 16 weeks during 2 years
- description
- time-to-progression with anti-angiogenic traitment evaluated by RECIST criteria
Secondary outcomes (2)
- measure
- Validation of the technical and acquisition measurement models
- timeFrame
- at day 7 and after every 6 at 16 weeks during 2 years
- description
- Validation of the technical and acquisition measurement models of tumor perfusion MRI and CT, and diffusion MRI, study of reproducibility
- measure
- Assessment of potential drug costs
- timeFrame
- at the end
- description
- Assessment of potential drug costs avoided by use of innovative prognostic criteria for adapting treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * with metastatic RCC * without previous recent antiangiogenic treatment Exclusion Criteria: * severe renal insufficiency * allergy to contrast agents * pregnancy
References
Publications (0)
Data not yet available